Acasti Pharma to Present Study

Acasti Pharma said Wednesday it will present a study of CaPre, a purified omega-3 phospholipid concentrate derived from krill oil, which is being developed to treat people with severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis.

Acasti has completed two phase 1 and two phase 2 clinical trials with CaPre for the treatment of hypertriglyceridemia, The outcome of a recent end-of-phase 2 meeting with the Food and Drug Administration confirmed that the phase 3 program is on track to start late 2017. “Data to be presented will highlight Acasti’s commitment to providing hypertriglyceridemia patients and treating physicians with a well-absorbing omega-3 therapeutic that may also have a positive impact on the major lipids associated with cardiovascular disease risk,” Chief Operating Officer Pierre Lemiuex.

Leave a Comment